Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Scientists probe gene activity in rare swelling disorder

NCT ID NCT04032002

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at gene activity in immune cells from 30 people with hereditary angioedema and healthy volunteers. The goal was to see if certain receptors on monocytes are linked to inflammation and blood vessel problems. No treatment was given; the study was purely observational to learn more about the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

30 people

The number who actually took part.

Started

Nov 2020

Finished

May 2021

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria (patients): * Patient with inherited bradykinic angioedema due to quantitative or qualitative C1-inhibitor deficiencies, regardless of the frequency or severity of seizures and regardless of their background treatment, with the following diagnostic criteria: * C1-inhibitor rate \<50% of normal * Repeated episodes characteristic of bradykinic angioedema * Hereditary nature of the disease. * Person who read and understood the newsletter and signed the consent form * Person affiliated with a social security scheme * Effective contraception in women of childbearing age (negative pregnancy test). For postmenopausal women, a confirmatory diagnosis should be obtained (amenorrhea for at least 12 months before the inclusion visit). Inclusion Criteria (volunteers): * Person affiliated with a social security scheme * Person who read and understood the newsletter and signed the consent form * Effective contraception in women of childbearing age (negative pregnancy test). For postmenopausal women, a confirmation diagnosis should be obtained (amenorrhea for at least 12 months before the inclusion visit) Exclusion Criteria (patients): * Angioedema crisis less than 1 month old * Chronic inflammatory disease such as rheumatoid arthritis or Crohn's disease. * Acute infection in progress, with or without anti-infectious treatment * Contraindication to the use of trinitrin: * Hypersensitivity to nitrates or to any of the excipients * shock, severe hypotension, * obstructive cardiomyopathy, * inferior court inferior myocardial infarction with right ventricular extension, except in case of evidence of left ventricular failure, * intracranial hypertension, * patient treated with sildenafil * Pregnant or parturient or breastfeeding woman or lack of proven contraception * Person deprived of liberty by an administrative or judicial decision or person placed under the protection of justice / sub-tutorship or curatorship * Patient participating or having participated in another therapeutic trial within one week. Exclusion Criteria (volunteers) * Chronic inflammatory disease such as rheumatoid arthritis or Crohn's disease. * Acute infection in progress, with or without anti-infectious treatment * Contraindication to the use of trinitrin: * Hypersensitivity to nitrates or to any of the excipients * shock, severe hypotension, * obstructive cardiomyopathy, * inferior court inferior myocardial infarction with right ventricular extension, except in case of evidence of left ventricular failure, * intracranial hypertension, * patient treated with sildenafil * Pregnant or parturient or breastfeeding woman or lack of proven contraception * Person deprived of liberty by an administrative or judicial decision or person placed under the protection of justice / sub-tutorship or curatorship * Person participating or having participated in another therapeutic trial within one week.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hereditary angioedema due to C1-inhibitor deficiency are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • DRCI

    Rouen, 76000, France